Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Boehringer And Anthem Put Stiolto Duo To Real World Test In COPD

Executive Summary

US noninferiority study mainly of Anthem beneficiaries aims to show if COPD patients are being overtreated with LABA/LAMA/ICS triple combos when a LABA/LAMA duo would do.

You may also be interested in...

GOLD Pushes LABA/LAMA Class In New COPD Treatment Update

New guidelines for the treatment of COPD could change the way this serious condition is managed, with knock-on effects for pharma companies with respiratory franchises.

Real-World Evidence: Lessons From GSK's Salford Lung Study

The Salford Lung Study is pioneering in the emerging field of gathering real-world evidence. David Leather, Global Medical Affairs Leader in the Respiratory Franchise at GSK, led the UK-based study and talked to the Pink Sheet about why it was important for GSK and what may come next.

Boehringer/WellPoint Outcomes Research To Inform Pradaxa Treatment

The study in non-valvular atrial fibrillation patients is the first project to launch under a five-year research agreement between Boehringer Ingelheim and WellPoint.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts